Celgene Share Price

CELG

Delayed Nasdaq Other stock markets 21:00:00 20/11/2019 GMT			5-day change	1st Jan Change
108.24 ^USD	+0.10%		-1.97%	+68.89%

14/06/23	Sutro Biopharma, Inc. Receives a Notice of Termination from Celgene Corporation	CI
08/09/21	Biocon Limited, Biocon Pharma Limited and Biocon Pharma Inc. Enters into A Confidential Settlement Agreement with Celgene Corporation	CI

on all subscriptions*

Exceptional extension!

Enjoy this offer

* See conditions under "Our services"

News in other languages: Celgene

07/04/21	DGAP-WpÜG: Angebot zum Erwerb / Zielgesellschaft: ; Bieter: qqqqq
25/03/21	Leonteq wird neue Emittentin an der BX Swiss AG im Segment «deriBX»
02/02/21	BX Swiss AG startet Handel in neuem Bondsegment
07/07/20	Die BX Swiss AG erhält von der FINMA die Zulassung zur Führung des Schweizer Beraterregisters
03/07/20	Möbel Markt mömax wird neuer Ankermieter im Rüti Center in Pratteln

More news

Celgene Corporation specializes in the design, development, and sale of products for treating cancer and immune system disorders. Net sales break down by product family as follows: - therapeutic products (99.9%); - other (0.1%): cellular therapy products and biological materials for implants, for tissue and organ treatments, and for therapeutic product development. Net sales are distributed geographically as follows: the United States (65.6%), Europe (24.7%) and other (9.7%).

Employees

Sector

More about the company

Market Cap	77.04B 67.68B 62.36B 58.38B 109B 7,298B 111B 749B 290B 3,581B 289B 283B 12,445B	P/E 2017	28.7x	P/E 2018	11.6x
Enterprise Value	91.26B 80.17B 73.87B 69.15B 130B 8,645B 132B 887B 343B 4,242B 343B 335B 14,742B	EV / Sales 2017	6.61x	EV / Sales 2018	3.86x
Free-Float	-	Yield 2017 *	-	Yield 2018	-

14/06/23	Sutro Biopharma, Inc. Receives a Notice of Termination from Celgene Corporation	CI
08/09/21	Biocon Limited, Biocon Pharma Limited and Biocon Pharma Inc. Enters into A Confidential Settlement Agreement with Celgene Corporation	CI
22/06/21	Celgene Corporation Will Grant Sun Pharmaceutical Industries Limited A License to Celgene's Patents Required to Manufacture and Sell Certain Limited Quantity	CI
22/02/21	Celgene Corporation Issues Notice of Redemption of Notes	CI
04/02/21	Bristol-Myers Squibb Company and Celgene Corporation Announce Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion	CI
04/01/21	Ikena Oncology, Inc. announced that it has received $120 million in funding from a group of investors	CI
22/12/20	Amgen : Signs Licensing Agreement With Medicines Development for Global Health	MT
05/11/20	Bristol Myers Squibb : Q3 Results Beat Estimates; Raises 2020 EPS Outlook	MT
22/09/20	Silverback Therapeutics, Inc. announced that it has received $84.999996 million in funding from a group of investors	CI
21/09/20	Silverback Therapeutics, Inc. announced that it expects to receive $84.999996 million in funding from a group of investors	CI
25/03/20	Agios Pharmaceuticals, Inc. Provides Update on 2016 Collaboration Agreement with Celgene	CI
10/03/20	Silverback Therapeutics, Inc. announced that it has received $68.400013 million in funding from a group of investors	CI
04/03/20	Pulmonary Fibrosis Foundation Launches Industry Consortium to Identify Biomarkers in Pulmonary Fibrosis	CI

28/02/23	BRISTOL MYERS SQUIBB CO : Other Events (form 8-K)	AQ
25/08/22	Not What The Doctor Ordered: Authorisation Application Withdrawn For Pharma Patent Settlement In Australia	AQ
29/07/22	Authorisation request for proposed settlement between pharmaceutical companies withdrawn	AQ
24/02/22	BRISTOL MYERS SQUIBB CO : Other Events (form 8-K)	AQ
04/08/21	Celgene : Sun Pharma And Celegene Settle Patent Dispute Over Lenalidomide (Revlimid®)	AQ

	2017	2018
Net sales	13B 11.42B 10.53B 9.85B 18.46B 1,232B 18.77B 126B 48.92B 604B 48.81B 47.76B 2,101B	15.28B 13.42B 12.37B 11.58B 21.7B 1,448B 22.06B 149B 57.49B 710B 57.36B 56.13B 2,469B
Net income	2.94B 2.58B 2.38B 2.23B 4.17B 279B 4.24B 28.58B 11.06B 137B 11.04B 10.8B 475B	4.05B 3.55B 3.28B 3.07B 5.74B 383B 5.84B 39.33B 15.22B 188B 15.19B 14.86B 654B
Net Debt	3.79B 3.33B 3.07B 2.87B 5.39B 359B 5.48B 36.87B 14.27B 176B 14.24B 13.93B 613B	14.22B 12.49B 11.51B 10.78B 20.19B 1,347B 20.53B 138B 53.51B 661B 53.39B 52.24B 2,297B

Celgene Share Price

Stocks

CELG

Valuation: Celgene

Latest news : Celgene

Press Releases: Celgene

News in other languages: Celgene

Quotes and Performance

Financials

Company Profile